AI Pathology
Visiopharm alternatives
13 tools that we compared head to head with Visiopharm in a written verdict. Each row says who the tool suits, according to that verdict, and links to the full comparison.
The list is not a ranking. Tools in the same category come first, then every group is in alphabetical order. A tool that is no longer sold is left out.
aetherAI
510(k) viewer clearance decided May 2024; customers include RWTH Aachen and University Hospital Frankfurt
See the review for plans
Full comparison
Aiforia
Aiforia Create builds custom image-analysis models; suites for breast, lung, prostate, colon and gastric
See the review for plans
Full comparison
Artera
Breast test cleared by FDA, K254115, May 2026; low or high distant-metastasis risk group
See the review for plans
Full comparison
Caris Life Sciences
PMA-approved MI Cancer Seek sequencing assay; vendor says EHR ordering at 3,100+ locations
See the review for plans
Full comparison
Freenome
PMA-approved, P250029, July 2026; blood test for colorectal screening, adults 45 and older
See the review for plans
Full comparison
GRAIL
Prescription-only blood test, CLIA lab; pATHFINDER 2 had 25,490 consented participants
See the review for plans
Full comparison
Ibex Medical Analytics
FDA 510(k) K241232 for prostate detection; cE marked solutions plus UK MHRA registration
See the review for plans
Full comparison
Indica Labs HALO AI
HALO AP Dx 510(k) cleared, K232833 and K252762; cleared with Aperio GT 450 DX and NanoZoomer S360MD
See the review for plans
Full comparison
PathAI AISight
AISight Dx cleared by FDA for primary diagnosis; cleared viewer works with two named scanners
See the review for plans
Full comparison
Proscia Concentriq
Cleared with Hamamatsu S360MD and Leica GT 450 DX; cloud deployment in the August 2026 clearance
See the review for plans
Full comparisonSectra Pathology
FDA 510(k) clearances March 2020 and April 2024; worklists, reporting and image review in IDS7
See the review for plans
Full comparison
Tempus Digital Pathology
Prostate Detect authorized by FDA under De Novo DEN200080; vendor-claimed 20% shorter reading time
See the review for plans
Full comparison
Vesta
Vesta Bladder risk scores and BCG response test; $22M Series A from DCVC and a16z
See the review for plans
Full comparison